Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Mustang Bio Inc(MBIO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MBIO
09/24/2026: MBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Mustang Bio Inc is a clinical-stage biotechnology company focused on developing CAR-T and gene therapies for cancer and genetic diseases. Its main strength lies in a specialized pipeline licensed from academic partners, though it lacks commercial products and consistent revenue. The primary growth opportunity rests on achieving positive clinical readouts that could lead to licensing deals or regulatory approvals. However, the company faces significant risks, including intense competition from larger, well-capitalized firms, and a constant need for external financing. This stock is suitable only for high-risk investors comfortable with binary outcomes, and investors should closely monitor upcoming clinical data readouts and the company's ongoing cash position.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to the biotech sector but lacks the consistent revenue growth typical of mature growth stocks. |
| Momentum investor | Weak fit | The stock often experiences high volatility and lacks sustained, long-term upward price momentum necessary for this style. |
| Value investor | Weak fit | The absence of earnings and positive cash flow makes standard value metrics inapplicable. |
| Dividend investor | Weak fit | Mustang Bio does not pay a dividend and prioritizes capital preservation for R&D. |
| Low-risk investor | Weak fit | The clinical-stage nature of the company involves high binary risk, making it unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause significant and rapid swings in the share price. |
| Valuation risk | High | Valuations are highly speculative due to the lack of commercial revenues. |
| Competition risk (Oncology/CAR-T) | High | Established players possess significantly more resources to capture market share. |
| Business quality | Medium | The company relies on a pipeline of early-to-mid-stage assets with uncertain outcomes. |
| Dividend income | Low / none | Income generation is not part of the business model. |
| Execution risk | High | Success depends entirely on the ability to conduct trials, meet regulatory standards, and secure funding. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -18.31% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.88M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 23.2K shares | Beta 2.05 | 52 Weeks Range 0.47 - 1.85 | Updated Date 09/24/2026 |
52 Weeks Range 0.47 - 1.85 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell and Gene Therapy R&D | Clinical trial development for oncology and genetic conditions. | The company does not generate revenue from product sales and currently operates by burning cash to fund research. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -13.24M | Price to Sales(TTM) 2205.73 |
Enterprise Value -13.24M | Price to Sales(TTM) 2205.73 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 6.73M | Shares Floating 6.19M |
Shares Outstanding 6.73M | Shares Floating 6.19M | ||
Percent Insiders 8.02 | Percent Institutions 9.93 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Mustang Bio Inc
Exchange NASDAQ | Headquarters Waltham, MA, United States | ||
IPO Launch date 2017-08-22 | President, CEO, Interim CFO & Director Dr. Manuel Litchman M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.mustangbio.com |
Full time employees 4 | Website https://www.mustangbio.com | ||
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.